• Publications
  • Influence
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
TLDR
In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events, and evidence-based glucagon-like peptide 1 receptor agonists should be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events.
Cerebrovascular disorders in patients with diabetes mellitus.
TLDR
The frequency of transient ischemic attacks is not increased in patients with diabetes compared to the general population and controversy exists regarding whether hyperglycemia adversely affects stroke outcome or primarily reflects stroke severity.
Stroke in patients with diabetes mellitus
The article's objective is to review the key advances in the scientific literature related to the association of stroke with diabetes mellitus and to summarize the current approaches to stroke
Treatment of Symptomatic Polyneuropathy With Actovegin in Type 2 Diabetic Patients
TLDR
Sequential intravenous and oral actovegin treatment over 160 days improved neuropathic symptoms, VPT, sensory function, and quality of life in type 2 diabetic patients with symptomatic polyneuropathy.
Prevalence and correlates of depressive disorders in people with Type 2 diabetes: results from the International Prevalence and Treatment of Diabetes
Aims To assess the prevalence and management of depressive disorders in people with Type 2 diabetes in different countries. Methods People with diabetes aged 18–65 years and treated in outpatient
Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs
TLDR
The new data on hospitalisation for heart failure with empagliflozin is discussed in the context of current evidence and clinical guidelines, as clinicians experienced in managing cardiovascular risk in patients with T2D.
Predictors of response to treatment with actovegin for 6 months in patients with type 2 diabetes and symptomatic polyneuropathy.
TLDR
Actovegin treatment was associated with a clinically meaningful response in neuropathic symptoms and/or impairments in patients with symptomatic DSPN and seems an appropriate therapy for the majority of patients with DSPn.
Prevalence and correlates of depressive disorders in people with Type 2 diabetes: results from the International Prevalence and Treatment of Diabetes and Depression (INTERPRET‐DD) study, a
TLDR
To assess the prevalence and management of depressive disorders in people with Type 2 diabetes in different countries, a large number of patients in these countries have had a history of depression.
The INTERPRET–DD study of diabetes and depression: a protocol
TLDR
The International Prevalence and Treatment of Diabetes and Depression Study (INTERPRET–DD) aims to address a dearth of knowledge and identify optimal pathways to care across the globe.
...
1
2
3
4
5
...